Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600
Debt
Debt-to-Equity Ratio0.42
Current Ratio4.71
Quick Ratio4.71
Price-To-Earnings
Trailing P/E Ratio-18.97
Forward P/E Ratio-23.49
P/E GrowthN/A
Sales & Book Value
Annual Sales$173.77 million
Price / Sales16.88
Cash FlowN/A
Price / CashN/A
Book Value$1.04 per share
Price / Book13.33
Profitability
EPS (Most Recent Fiscal Year)($0.73)
Net Income$-147,340,000.00
Net Margins-84.79%
Return on Equity-80.54%
Return on Assets-33.50%
Miscellaneous
Employees298
Outstanding Shares211,670,000
Market Cap$2.98 billion
Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions
What is Array Biopharma's stock symbol?
Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."
How were Array Biopharma's earnings last quarter?
Array Biopharma Inc (NASDAQ:ARRY) announced its earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.01. The biopharmaceutical company earned $35.40 million during the quarter, compared to analysts' expectations of $38.73 million. Array Biopharma had a negative return on equity of 80.54% and a negative net margin of 84.79%. The firm's revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. View Array Biopharma's Earnings History.
When is Array Biopharma's next earnings date?
What price target have analysts set for ARRY?
9 Wall Street analysts have issued 12 month target prices for Array Biopharma's stock. Their forecasts range from $13.00 to $33.00. On average, they expect Array Biopharma's stock price to reach $21.5556 in the next year. This suggests a possible upside of 55.5% from the stock's current price. View Analyst Price Targets for Array Biopharma.
What is the consensus analysts' recommendation for Array Biopharma?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Array Biopharma.
What are Wall Street analysts saying about Array Biopharma stock?
Here are some recent quotes from research analysts about Array Biopharma stock:
- 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/17/2018)
- 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating with an updated $26 PT on ARRY shares. The company has an upcoming PDUFA of 6/30/18 for the combination of binimetinib/encorafenib (bini/enco), which, based on the results of the COLUMBUS study, has the potential to be best-in-class and take a market-leader position, in our view. In addition, we see further opportunity in BRAF+ CRC based on the safety lead-in portion data presented to date from the BEACON-CRC study." (6/24/2018)
Who are some of Array Biopharma's key competitors?
Some companies that are related to Array Biopharma include Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Perrigo (PRGO), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Beigene (BGNE), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amneal Pharmaceuticals (AMRX), Dr.Reddy's Laboratories (RDY) and United Therapeutics (UTHR).
Who are Array Biopharma's key executives?
Array Biopharma's management team includes the folowing people:
- Mr. Ron Squarer, Chief Exec. Officer and Director (Age 51)
- Mr. Jason Haddock, Chief Financial Officer (Age 48)
- Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)
- Dr. Victor Sandor M.D., C.M, Chief Medical Officer (Age 52)
- Dr. Nicholas A. Saccomano Ph.D., Chief Scientific Officer (Age 59)
Has Array Biopharma been receiving favorable news coverage?
Headlines about ARRY stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Array Biopharma earned a news impact score of 0.02 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 45.58 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Array Biopharma.
Who are Array Biopharma's major shareholders?
Array Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.58%), BlackRock Inc. (8.03%), Morgan Stanley (1.70%), American Century Companies Inc. (1.24%), First Light Asset Management LLC (1.14%) and Pinnacle Associates Ltd. (1.05%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.
Which major investors are selling Array Biopharma stock?
ARRY stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., United Services Automobile Association, Wells Fargo & Company MN, BNP Paribas Arbitrage SA, International Biotechnology Trust PLC, BlueMountain Capital Management LLC, Handelsbanken Fonder AB and MetLife Investment Advisors LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.
Which major investors are buying Array Biopharma stock?
ARRY stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, American Century Companies Inc., BlackRock Inc., Voya Investment Management LLC, FMR LLC, First Light Asset Management LLC, Columbus Circle Investors and Canada Pension Plan Investment Board. View Insider Buying and Selling for Array Biopharma.
How do I buy shares of Array Biopharma?
Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Array Biopharma's stock price today?
One share of ARRY stock can currently be purchased for approximately $13.86.
How big of a company is Array Biopharma?
Array Biopharma has a market capitalization of $2.98 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.
How can I contact Array Biopharma?
Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]opharma.com.
MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
